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Uncertainty exists about the effect of antiepileptic drugs on gonadal function. In females, long-term valproate treatment has
been shown to induce endocrine disturbances and an increased number of ovarian cysts. The aim of the present study was
to investigate whether valproate can also induce morphological changes in the testis of male animals. In addition, possible
morphological changes in the liver, heart, lungs, lymphatic nodes, pancreas, kidney or brain were studied. The carcinogenic im-
plications were evaluated by the measurement of p53. Male Wistar rats were fed perorally with valproate mixture 200 mg kg−1
(n = 15) or 400 mg kg−1 (n = 20), or control solution (n = 15) twice daily for 90 days. Serum concentrations measured
4–6 hours after the last dose were 105 and 404 µmol l−1 in low- and high-dose valproate treated animals respectively. There
was a highly significant, 51% decrease (P< 0.001) in testicular weight in the high-dose treated valproate rats with no changes
in the other groups. There was widespread testicular atrophy with histologically verified spermatogenic arrest in 15/20 of the
high-dose valproate treated animals. No changes in the testis were seen in the low-dose valproate treated rats, nor in the control
rats. There were no morphological changes in the other investigated organs. None of the groups showed over-expression of p53.
In conclusion, a dose-dependent effect of chronic valproate treatment was found on testicular morphology in rats. Caution must
be taken before these results can be applied to humans.
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INTRODUCTION
There is increasing concern about the effect of
antiepileptic drugs (AEDs) on male reproduction. Sex-
ual dysfunction, including reduced potency and hypo-
sexuality is seen in as much as 38–71% of men with
epilepsy1–4. This may, at least in part, be due to long-
term use of AEDs which have been shown to induce
disturbances in sex hormone levels2, 5–9 and also to re-
duce sperm quality5, 10–13. These effects have so far
not been related to specific drugs. In women, how-
ever, menstrual disorders, polycystic ovaries and hy-
perandrogenism were found in some recent studies af-
ter long-term valproate treatment14–18. This could in-
dicate a drug-specific effect of valproate on ovarian
morphology and female sex hormones.
In males, testicular atrophy has previously been
shown in both rats and dogs after chronic valproate
treatment19. This has, however, been attributed to
doses far above those used when treating humans. In
addition, chronic valproate treatment has also been
shown to slow pubertal maturation by decreasing
the rate of testicular growth and spermatogenesis in
mice20. In the clinical setting there is sparse informa-
tion over the possible hormonal effects of valproate
in males. In a recent study, 12/20 male patients tak-
ing valproate showed increased androgen levels21.
Further, in a case study Yerby and McCoy13 found
markedly reduced sperm quality in a man on val-
proate, which improved after change of medication to
felbamate.
Recently, long-term treatment with valproate has
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been shown to increase significantly the amount of
polycystic ovaries in non-epileptic female Wistar rats
at serum concentrations within the human therapeutic
range22, 23. By using a corresponding animal model,
we wanted to study the effects of long-term valproate
treatment also in male rats by investigating testicu-
lar morphology at serum concentrations within ther-
apeutic range in humans. In addition, specific analy-
ses were performed to investigate a possible relation
between morphological changes and carcinogenicity.
This was done by measuring the expression of the tu-
mour suppressor gene p53, and by performing flow cy-
tometric DNA measurements of the testis.
MATERIALS AND METHODS
Seventy male Wistar rats (Møllegaards Avlslaborato-
rium, Skensved, Denmark) were fed perorally through
a gastric tube with valproate mixture or placebo solu-
tion twice daily for 90 days. All animals were at the
age of 80 days at the beginning of the study. They
were caged in triplets in Macrolon III cages at constant
temperature and humidity on a 12 hour light and dark-
ness schedule at an air exchange rate of 18 changes per
hour. The rats were kept on B&K pelleted rat diet and
given tap water ad libitum. The animals were tested
negative for parasitical, bacterial and viral agents ac-
cording to the recommendations of the Federation
of Laboratory Animal Science Association24. Animal
care was in accordance with institutional guidelines
and national legislation. The animal ethical commit-
tee at the National Hospital, University of Oslo, Oslo,
Norway approved the study.
A standard commercially available valproate mix-
ture was used together with a placebo solution (gift
from Desitin Pharma AS, Norway). The animals were
separated into four different groups, receiving either
valproate 200 mg kg−1 per dose (n = 15), valproate
400 mg kg−1 per dose (n = 20) or placebo solution
(n = 15), twice daily. The animals were given half-
daily doses the first week. They were weighed at the
first day of the study, and the doses were later ad-
justed according to weight changes every week. Af-
ter 90 days, all animals were weighed and thereafter
killed. This was done by means of exsanguination un-
der pentobarbital narcosis by abdominal artery punc-
ture, 4–6 hours after their last medication intake. The
blood was collected and serum frozen at −20 ◦C un-
til analysis. Each testicle was weighed separately and
immediately cut in two pieces. One half was forma-
lin fixed in 4% buffered formaldehyde for morpholog-
ical and immunohistochemical examination. The other
half of the testis was immediately stored at−70 ◦C un-
til further analysis.
Histology
In addition to testicular tissue, specimens of liver, pan-
creas, kidney, lung, heart, lymph nodes and brain in-
cluding both hemispheres, brainstem and cerebellum,
were fixed in 4% buffered formaldehyde. The spec-
imens were routinely processed, embedded in paraf-
fin, and 5 µm thick sections were cut and stained
with haematoxylin and eosin for light microscopic
evaluation. Two independent pathologists performed a
blinded microscopic evaluation of the sections of the
testes (AaB and KAB).
Immunohistochemistry
For immunohistochemistry 2–5 µm thick sections
were mounted on silane-coated slides, deparaffinized
and rehydrated. A mouse monoclonal p53 antibody
(Oncogene Science) and a polyclonal rabbit anti-
human testosterone antibody (BioGenex Laborato-
ries, San Ramon, CA, USA) were used as primary
antibodies.
Staining for p53
The slides were incubated with p53 antibody diluted
1:100. Staining was performed with labelled Avidin–
Biotin (LAB)25, 26. We microwaved the sections (2 ×
5 min) in a citratebuffer prior to immunohistochem-
istry. Positive and negative controls included substitu-
tion of the primary antiserum with normal serum from
the same species in which the antibody was made.
Only nuclear staining was regarded as positive.
Staining for testosterone
A streptavidin alkaline phosphatase method was used.
Sections were treated with a solution containing 30%
fat-free dried milk (Nestle` SA, Vevey, Switzerland)
for 20 minutes before incubation with a polyclonal
antibody (BioGenex Laboratorium, San Ramon, CA,
USA) diluted 1 : 50 in Tris buffered saline containing
2.5% bovine serum albumin (TBS/BSA). Biotinylated
goat anti-rabbit Ig (DAKO A/S, Glostrup, Denmark)
diluted 1 : 500 in TBS/BSA was used as a secondary
antibody. Streptavidin alkaline phosphatase (Amer-
sham plc, Bucks, UK) diluted 1 : 500 were applied to
the sections. Incubations were in a dark moist cham-
ber for 30 minutes, and washing between each of the
steps was in TBS for 5 minutes. Alkaline phosphatase
substrate containing Fast Red TR salt (Sigma-Aldrich
Corporation, St Louis, MO, USA) was applied for
20 minutes. Subsequently, the sections were rinsed in
tap water and counterstained with Mayer’s modified
haematoxylin. In the control sections, the primary an-
tibody was replaced by normal rabbit serum diluted
1:100 in TBS/BSA.
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Flow cytometric DNA measurements (FCM)
Nuclear suspensions were prepared from thawed, fresh
frozen testicular specimens that were minced in slices
in 10 mM phosphate buffer and filtered through a
50 µm filter. The preparation and staining of nuclei
for FCM was performed according to the detergent–
trypsin method developed by Vindeløv et al.27 using
solutions containing trypsin 0.003 mg ml−1 trypsin in-
hibitor 0.50 mg ml−1, ribonuclease. A 0.01 mg ml−1,
spermin tetrachloride 0.01 mg/ml and propidum io-
dide 0.41 mg ml−1. A single cell suspension from each
specimen was mixed with a suspension of chicken and
rainbow trout red blood cells for internal DNA stan-
dards.
The nuclear DNA content was measured in a FACS
caliber flow cytometer. An argon ion laser from which
the 488 nm line was used produced the excitation
light. The output signals were sorted by a 256-channel
analyser and were presented as histograms. The DNA
amount was calculated in relation to the two internal
standards, chicken and trout erythrocytes.
Valproate serum concentrations
Serum concentrations of valproate were analysed by a
fluorescence polarization immunoassay system using
an AxSym analyser (Abbott Diagnostic Division, Irv-
ing, TX). The sensitivity of the valproate assay was
5.0 µmol l−1, and the intra-assay and inter-assay vari-
ations were 1.8% and 2.7% respectively.
Statistics
The mean and standard deviation for all analyses
were calculated. The statistical analyses were per-
formed with a one-way ANOVA technique using
a commercially available software package (SPSS)
for all data. Not normally distributed data, including
serum VPA concentrations, were analysed with a non-
parametric Kruskal–Wallis test (specified in tables). A
chi-squared test was performed when appropriate.
RESULTS
All animals tolerated the treatment and the gastric tube
feeding without any signs of discomfort, and none of
the animals died during the study. There was no reduc-
tion in motor activity or any observed changes of the
thriving in the animals.
Median serum concentrations of valproate at time
of death 4–6 hours after the last dose were 105 and
404 µmol l−1 in low- and high-dose treated animals.
Examinations of median valproate serum concentra-
tions in 12 of the animals from the high-dose group
at different time intervals were 1152, 599, 286 and
119 µmol l−1 measured 2, 4, 6 and 8 hours after the
last dose respectively.
Morphological findings
Animal weight was unchanged in the low-dose group,
while there was a statistically significant, 15% reduc-
tion in body weight in high-dose treated animals com-
pared to control animals (P< 0.001, Table 1).
Table 1: Animal weight, testicular weight and ratio of
testicular weight/animal weight after long-term treatment with
valproate (VPA) and control solution in male Wistar rats.
Control Low-dose High-dose
(n = 15) VPA (n = 15) VPA (n = 20)
Animal weight
Mean 440.60 422.20 374.50
St. dev 27.80 27.45 21.74
P — <0.001c <0.001a,b
Testicular weight
Mean 1.9051 1.8138 0.9288
St. dev 0.1664 0.1664 0.3531
P — <0.001c <0.001a,b
Ratio
Mean 0.0043 0.0043 0.0025
St. dev 0.0007 0.0004 0.001
P — <0.001c <0.001a,b
a Compared to control; b compared to low-dose VPA; c compared
to high-dose VPA.
Testicular weight in the high-dose treated ani-
mals showed a significant, 51% and 49% decrease
(P< 0.001, Table 1) compared to control and low-dose
treated animals respectively.
The ratio of testicular weight/animal weight was sig-
nificantly lower in the animals receiving high-dose
valproate (P< 0.001, Table 1) compared to all other
groups. This ratio was unchanged in the low-dose val-
proate treated animals compared to control or lamot-
rigine treated animals (Table 1).
On the basis of the light microscopical findings
in the testicles, the animals were now classified into
four groups (Table 2). Groups A—normal findings,
group B—slight atrophy, group C—moderate, diffuse
atrophy and group D—extensive diffuse atrophy. Fif-
teen of the 20 high-dose valproate treated animals had
moderate to severe testicular atrophy characteristics of
groups C and D (Figs 1 and 2). These animals deviated
significantly (P< 0.001) from both the controls and
the low-dose treated animals. The tubuli seminiferi of
the animals included in groups C and D were mostly
atrophic. In the affected tubuli, the most advanced cell
type was primary spermatocytes. There was no sign of
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round spermatids in the tubuli categorized in groups C
and D (Fig. 3). The Leydig cells did not appear to be
affected. All the animals treated with low-dose val-
proate were found in groups 1 and 2, and this was not
significantly different from the controls.
Table 2: Light microscopical findings in rat testicles after VPA
treatment.
Control Low-dose VPA High-dose VPA
(n = 15) (n = 15) (n = 20)
A 14 14 1
B 1 1 4
C 0 0 8
D 0 0 7
C + D 0 0 15∗
∗ P < 0.001, chi-squared test, compared to control. A: normal
findings; B: slight atrophy; C: moderate atrophy; D: extensive
atrophy.
Fig. 1: Macroscopic cross-sections of the testicles of (a) a
control rat and (b) a valproate high-dose treated rat.
Fig. 2: Photomicrograph (×200) of cross-sections of
seminiferous epithelium in (a) a control rat and (b) a
valproate high-dose treated rat.
Fig. 3: (a) Photomicrograph (×400) of a partial cross-section
of seminiferous epithelium showing intact epithelium in a
control rat. (b) Photomicrograph (×400) of a partial
cross-section of seminiferous epithelium demonstrating
degenerated epithelium in a high-dose valproate treated rat.
S = Sertoli cell, Spg = spermatogonium, Spc =
spermatocyte St.8 = Stage 841.
Fig. 4: (a) Testis of a control rat stained with an antibody
against testosterone. Positive staining of interstitial cells is
observed between normal seminiferous tubules. Streptavidin
alkaline phosphatase method (×260).
(b) Immunocytochemistry of a testis of a rat treated with
high-dose valproate. Positive staining for testosterone is
observed in interstitial cells. Note the severe atrophy of the
adjacent seminiferous tubules. Streptavidine alkaline
phosphatase method (×260).
One of the low-dose treated animals had light mi-
croscopical findings of focal myocarditis, none of the
high-dose treated animals showed similar changes.
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This was not significantly different from the controls
where two animals had focal myocarditis (Table 3).
Four of the animals receiving low-dose valproate, and
six that were given high-dose valproate, had an abun-
dance of mast cells in the lymph nodes investigated.
This did not differ from the controls where four ani-
mals had similar changes.
Table 3: Pathological findings in the heart, lung, lymphatic
tissue, kidney, liver and CNS of male Wistar rats after
long-term valproate treatment.
Hearta Lung Lymphatic Kidney Liver CNS
tissueb
Control (n = 15) 2 0 4 0 0 0
(n = 15)
Low-dose VPA (n = 15) 1 0 4 0 0 0
(n = 15)
High-dose VPA 0 0 6 0 0 0
(n = 20)
a Focal myocarditis; b abundance of mast cells.
There were no morphological changes in the lungs,
the kidneys, liver or central nervous system (CNS) in
any of the two valproate treated groups, similar to the
findings in the controls.
Flow cytometric results
All specimens were diploid, mean CV 3.7 (2.7–5.2)
(CV = coefficient of variations of signals within the
main peak, providing a measurement of the peak
width). There were no significant differences between
the different treatment groups with mean CV in val-
proate low-dose treated animals 3.5; in valproate high-
dose treated 3.2; and 3.9 in control treated animals.
Aneuploid cell populations were not detected in either
of the groups.
Immunohistochemistry
Neither the valproate high-dose treated, nor the
valproate low-dose treated animals showed over-
expression of p53 in the testis. This is in concurrence
with the findings in the control rats.
Examination of sections of testes stained for testos-
terone showed positive reactivity in Leydig cells and
some staining of interstitial connective tissue (Fig. 4).
Differences in staining distribution and intensity of
Leydig cells were not observed between the treated
rats and the control animals. No staining was observed
in the negative control slides.
DISCUSSION
Our main findings are the significant occurrence of
testicular atrophy and the spermatogenic arrest af-
ter long-term treatment with high-dose valproate in
rats. Walker et al.19 demonstrated reduced or absent
spermatogenesis and testicular atrophy in rats given
valproate 1200 and 1600 mg kg−1 for 13 weeks. The
doses were considerably higher than in our study, but
serum concentrations were not measured. In the same
study, dogs were given valproate 150–400 mg kg−1 for
13 weeks. These valproate doses were much lower, but
again the principal pathologic finding was moderate
to severe testicular atrophy, with degeneration of germ
cells, suppression of spermatogenesis and interstitial
fibrosis.
To evaluate the possible clinical implications of
drug effects observed in animal studies, it is of crucial
importance that the serum concentrations used can
be applied to a clinical setting. The extensive testic-
ular atrophy demonstrated in our study were found
at serum valproate concentrations considered within,
or even in the lower part of therapeutic range in hu-
mans, 4–6 hours after the last dose. Furthermore, the
concentrations more than 6 hours after the last dose
were regularly below therapeutic range. Although the
maximum serum concentrations in our rats measured
2 hours after the last dose were about twice the max-
imum therapeutic range, it must be emphasized that
the therapeutic range of 300–600 µmol l−1 in humans
represents minimum concentrations. It is also well
known that due to the kinetics of the drug, diurnal
fluctuations in the range of several hundred percent
occur28, 29. It should also be noted that the doses
given to achieve a certain concentration are consid-
erably higher in rats than in humans, because of the
much shorter half-life of the drug in rats. In addition,
it is known that the serum concentration in mice and
rats necessary for an anticonvulsant effect is actually
nearly twice that of humans30. We therefore consider
the concentrations achieved in our high-dose treated
animals to be of clinical interest also when treating
humans.
Previous studies have shown that epilepsy itself can
induce hormonal disturbances in both males and fe-
males32, 33. In women, a relation between left-sided
temporal epileptic foci and the development of poly-
cystic ovaries has even been found34. It has therefore
been implied that the significant increase of polycys-
tic ovaries and hormonal disturbances in women using
valproate14, 15, is due to the epilepsy itself or by the se-
lection of patients since laterality was not considered
in these studies35. Randomly selected non-epileptic
animals are used both in the present study, and in the
previously published data in female rats23. Both stud-
ies demonstrate that valproate induces gonadal mor-
phological changes. This supports the view that there
is a drug-specific effect of valproate on gonadal mor-
phology.
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A drug-specific effect of valproate also gains some
support from the study by Cohn et al.11 in which male
rats received different antiepileptic drugs for a pe-
riod of 3 months. Both carbamazepine treated and val-
proate treated rats had diminished sperm content, but
the valproate treated animals were the only ones with
significantly decreased fertility. This does not, how-
ever, underscore the fact that changes in sex hormones
and semen quality may also occur using a wide variety
of other antiepileptic drugs2, 8, 9, 11, 20, 36, 37.
Morphological changes could not be found in any
other organ in any of the long-term valproate treated
animals. This is identical to our findings in the newly
published study of female rats23. Here we found a sig-
nificant increase in polycystic ovaries in female Wistar
rats given high-dose valproate, whereas other organs
were spared. These studies together suggest a gonadal-
specific effect of valproate. The results in our male
animals are also in concurrence with the findings of
Walker19, who suggested that the testis could be a tar-
get organ for valproate toxicity.
The morphological findings in the gonads of male
and female animals together with the well-known ter-
atogenic effect of valproate may suggest a possible in-
terference with gene expression. This possibility made
it interesting also to study the expression of p53, and
to perform flow cytometry. The p53 gene is regarded
as one of the most frequently mutated genes associ-
ated with cancer development. More than 50% of hu-
man primary tumour cells over-express a variety of
mutant p53 protein forms38, 39. Most seminomatous
and non-seminomatous germ cell tumours exhibit in-
creased p53 protein expression evaluated by immuno-
histochemistry40. The atrophic testis of the high-dose
treated valproate animals in our study showed no over-
expression of p53, weighing against a carcinogenic ef-
fect of the drug as evaluated by p53 expression. This
is in accordance with the flow cytometric results; cells
with abnormal DNA were not detected. Further differ-
entiation of the cells on the basis of flow cytometry is
inconclusive, most probably due to the frozen mate-
rial. The light microscopical findings were, however,
unambiguous.
The spermatogenesis was evaluated by way of
histological verification of the different cells in
the spermatogenetic cycle, which is an established
method31, 41. In the atrophic tubuli none of the cells
advanced beyond the stage of prophase of meiosis
I which is known to be very sensitive to toxicolog-
ical influence. Although no haploid cells were de-
tected in any of the atrophied tubuli, different stages
of the spermatogenesis could be visualized. Some
tubuli had apparently an abundance of cells; they
were clearly more irregularly situated than in the
species with normal tubuli. In more advanced cases,
empty spaces ‘shadows’ of epithelium were seen, cor-
responding to the space normally occupied by germ
cells, due to lack of these cell lines in the sper-
matogenesis. The tubuli showing the most extensive
atrophy resembled the pathological findings arising
in other testicular degenerations due to toxic sub-
stances42, 43.
Immunohistochemistry indicated an unchanged pat-
tern of testosterone staining. This could be interpreted
as a demonstration of unchanged number and activ-
ity of Leydig cells. The light microscopical findings,
showing no morphological changes in the Leydig cells
in either of the groups, supports this and is in accor-
dance with the changes restricted to the germ cells in
the study by Walker19. Atrophic seminiferous tubules
were found in rats given toxic doses of valproate at
1600 mg kg−1 per day. There was a virtual total loss
of germinal epithelium, while only minimal, if any, ef-
fect on the interstitial tissue was observed. Intact Ley-
dig cell function might also be implicated in the case
study of Yerby and McCoy13, who showed that in a
male patient changing medication from valproate to
felbamate had an improvement in semen quality with
no change in endocrine function as evaluated by FSH
and LH.
In conclusion, the present study has shown a drug-
specific effect of valproate on testicular morphology in
non-epileptic male rats at serum concentrations within
the therapeutic range in humans. However, caution
must be taken before these results can be applied to
humans. Our findings do however, encourage further,
both animal and human, studies to reveal the clinical
implications of these findings when treating epileptic
patients.
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